PGEN vs PHIO

Precigen, Inc. vs Phio Pharmaceuticals Corp. — Valuation Comparison 2026

PGEN

Biotechnology
Precigen, Inc.
Quality
4.3
out of 10
Value Trap
34
LOW
Price
$4.51
Last close
Models
4/13
Active
VS

PHIO

Biotechnology
Phio Pharmaceuticals Corp.
Quality
3.7
out of 10
Value Trap
39
LOW
Price
$1.14
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PGEN Fair ValuePGEN Upside PHIO Fair ValuePHIO Upside
Bayesian DCF Intrinsic $1.09 -75.8% $1.11 -2.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.40 -91.1% $1.64 +43.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PGEN vs PHIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PGEN vs PHIO — Which Stock Is More Undervalued?

PGEN scores higher with a 4.3/10 quality rating vs PHIO's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Precigen, Inc. (PGEN) and Phio Pharmaceuticals Corp. (PHIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PGEN currently trades at $4.51 with a QOC of 4.3/10, while PHIO trades at $1.14 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).